Amrubicin (Amr) Versus Docetaxel (Dtx) As Second- or Third-Line Treatment for Non-Small Cell Lung Cancer (Nsclc): a Randomized Phase III Trial

N. Katakami, H. Yoshioka,H. Okamoto,Y. Iwamoto, T. Seto,T. Takahashi,N. Sunaga,S. Kudoh, K. Chikamori, M. Harada, H. Tanaka, H. Saka, K. Takeda, N. Nogami, N. Masuda, T. Harada, N. Yamamoto,K. Nakagawa

Annals of oncology : official journal of the European Society for Medical Oncology（2014）

引用 3|浏览15

暂无评分

摘要

Aim: DTX is one of the standard drugs for patients (pts) with previously treated NSCLC. However, its efficacy seems insufficient. The efficacy of AMR for NSCLC has been previously reported. Thus, we conducted a randomized phase III trial comparing AMR to DTX, sponsored by Dainippon Sumitomo Pharma Co., Ltd.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要